Women whose breast cancer has quietly outmaneuvered their hormone treatment now have a fresh option in the UAE, where regulators have signed off on a pill that the rest of the world has yet to approve.
The drug, Etcamah®, targets a narrow but difficult group of patients: those with advanced or metastatic breast cancer who pick up an ESR1 gene mutation. That mutation tends to surface partway through endocrine therapy, and once it does, the hormone treatment that was holding the disease in check starts to lose its grip.
Camizestrant is the compound doing the work. Classed as a next-generation oral selective estrogen receptor degrader and a full estrogen receptor antagonist, it represents the newest tier in a family of medicines built to interrupt hormone-driven tumours. In many of these cancers, estrogen receptors behave like an ignition for growth and spread. The drug shuts those receptors down and breaks them apart, severing the signal the cancer depends on. Patients take it by mouth alongside a CDK4/6 inhibitor, a drug type that already has an established place in breast cancer care.
The clearance came from the Emirates Drug Establishment, which weighed the medicine’s quality, safety and efficacy along with the clinical evidence behind it before granting approval. That evidence rested on the Phase III SERENA-6 trial. In that study, patients who developed the mutation during endocrine therapy showed measurable gains in how long they went without their disease worsening — improvements the EDE described as both statistically and clinically significant.
Dr Fatima Al Kaabi, Director-General of the EDE, tied the approval to the speed and rigour of the country’s regulatory machinery, saying it reflects how efficiently the UAE evaluates and takes on new pharmaceutical science. She framed the decision as evidence that the national system is ready to deliver advanced options to patients.
“This milestone will further strengthen the UAE’s commitment to building a flexible pharmaceutical ecosystem capable of anticipating global scientific developments and keeping pace with the rapid evolution of the pharmaceutical sector,” Al Kaabi was quoted as saying by Gulf News. “Through advanced assessment tools that balance accelerated access with the highest standards of safety and quality, we will continue to reinforce the UAE’s position as a trusted reference point for pharmaceutical innovation.”
For AstraZeneca, the green light marks another expansion of the treatment menu for a disease that ranks among the most common cancers in women. Sameh El Fangary, the company’s Gulf Country President, said the move signals confidence in the science behind the medicine and called it a meaningful addition to breast cancer care.
“We look forward to strengthening collaboration with partners across the UAE to help improve treatment outcomes for eligible patients,” El Fangary said.
The EDE used the announcement to press a broader point on patient care, urging women not to neglect early screening, to stay with their prescribed regimens, and to keep up regular check-ins with their doctors — habits the authority says carry real weight in how well treatment works and how recovery unfolds.
